The yearly incidence of stroke in patients with atrial fibrillation is about 5 % \[[@CR1]\], which is 5 times higher than in comparable populations in sinus rhythm. The stroke risk largely depends on the underlying heart disease. In 'lone' atrial fibrillation (absence of heart disease) the stroke risk is only 0.5 % per year \[[@CR2]\], whereas in atrial fibrillation associated with rheumatic valvular heart disease, such as mitral valve stenosis, it is very high. Also in other heart diseases when atrial fibrillation is absent, such as congestive heart failure, the stroke risk is elevated \[[@CR3]\].

The classical anticoagulants {#Sec1}
============================

The coagulation cascade is a complex system, which can be activated by an intrinsic pathway (blood stasis and contact activation) or an extrinsic pathway (exposed tissue after vascular damage). The final common pathway from these two potential stimuli starts with the activation of plasma factor X into activated factor Xa (Fig. [1](#Fig1){ref-type="fig"}). Through activation of factor V, factor II (prothrombin) is activated to thrombin, the aggressive compound splitting fibrinogen into fibrin, which is the matrix of blood clots. The coagulation system is a real cascade. One molecule of factor Xa induces the formation of 50 thrombin molecules. Factor Xa and thrombin are counteracted by the naturally occurring antithrombin-III.Fig. 1Simplified diagram showing the coagulation cascade

Until recently, the only available oral anticoagulants were the coumarin derivatives. These compounds block the vitamin K dependent liver production of the plasma coagulation factors II, VII, IX and X. They are usually called vitamin K antagonists and have a relatively narrow therapeutic window, which is due to dose response, food and genetic variation. Therefore, vitamin K antagonists require close monitoring: overdosing may result in life-threatening bleeding and underdosing in inefficacy. An international and uniform laboratory standard of the intensity of anticoagulation has been introduced: the International Normalised Ratio (INR) replacing the non-standardised prothrombin time and Quick tests. Nevertheless, monitoring remains cumbersome and less than two-thirds of patients on chronic vitamin K antagonist therapy are within the therapeutic window.

Warfarin therapy is the cornerstone in the prevention of thromboembolism in patients with atrial fibrillation. Stroke in patients with persistent or permanent non-valvular atrial fibrillation can be reduced by 67 % by the use of oral anticoagulants \[[@CR4]\]. Severe bleeding with warfarin is seen in 1 out of 100 patients per year, which is double the risk of stroke in lone atrial fibrillation. Therefore, anticoagulation is only indicated in atrial fibrillation patients with a stroke risk that exceeds the risk of severe bleeding. Risk stratification for stroke in atrial fibrillation is now widely accepted with the CHA~2~DS~2~VASc score \[[@CR5]\], where patients with a score of 1 and higher are candidates for oral anticoagulation (Table [1](#Tab1){ref-type="table"}). In atrial fibrillation also the presence of aortic plaque is associated with an elevated stroke risk \[[@CR6]\]. The optimal target INR for patients on vitamin K antagonists is between 2.0 and 3.0 \[[@CR7]\]. In the Netherlands a higher target INR is advised, but this has never been confirmed to be more effective and/or safer in atrial fibrillation than the internationally accepted target range. In selected patients with atrial fibrillation, vitamin K antagonists have to be interrupted for surgical procedures, but in those undergoing pulmonary vein isolation they can be continued \[[@CR8]\].Table 1CHA~2~DS~2~VASc score points for prediction of stroke in atrial fibrillation \[[@CR5]\]Risk factorPointsAge 65--75 years1Age over 75 years2Female gender1Coronary or peripheral artery disease1Previous stroke2Hypertension1Symptoms or signs of left ventricular dysfunction1Diabetes mellitus1

Yet, the use of vitamin K antagonists is associated with the risk of severe and even fatal bleeding. Many physicians are reluctant to prescribe warfarin to the elderly patient with atrial fibrillation because of the risk of bleeding, and many are convinced that aspirin is a wise and acceptable alternative. However, there are now reassuring comparative data in the very elderly (over 75 years) showing superiority of warfarin over aspirin with equal bleeding risk for both therapies \[[@CR9]\]. This is one of the reasons antiplatelet therapy is now discouraged in stroke prevention in the European guidelines \[[@CR5]\].

The new oral anticoagulants {#Sec2}
===========================

In the past decade several oral direct inhibitors of thrombin and of factor Xa have been developed (Table [2](#Tab2){ref-type="table"}). They proved to be specific antagonists and show a dose-efficacy relationship. A major advantage is that there does not seem to be any drug tolerance and food interaction, and monitoring is not needed with these agents. They have a fast onset of activity and a relatively short duration of action, which in case of bleeding or planned surgery is another advantage over vitamin K antagonists. On the other hand, some agents need twice daily dosing and the fast offset of action may be problematic in case of poor compliance, e.g. when the patient does not take 2 or 3 doses in sequence. This disadvantage is not seen with warfarin, which has a very slow offset of action. Furthermore, an antidote algorithm for the novel oral anticoagulants has not been developed yet, while this is well established for warfarin.Table 2The new oral anticoagulantsClassNameT ½ (h)DosingExcretionAnti-IIa (antithrombin)Dabigatran (Pradaxa^R^)7--9b.i.d.80 % kidney, 20 % liverAnti-XaApixaban (Eliquis^R^)8--15b.i.d.21 % kidney, 78 % liverRivaroxaban (Xarelto^R^)9--12qd33 % kidney, 66 % liverEdoxaban (Lixiana^R^)^a^8--10qd35 % kidney, 65 % liver*IIa* activated factor II (thrombin), *Xa* activated factor X, *T* ½ (*h*) plasma half-life (hours), *b*.*i*.*d*. twice daily, *qd* once daily^a^not yet approved

The advantages and disadvantages of the novel oral anticoagulants relative to vitamin K antagonists are summarised in Table [3](#Tab3){ref-type="table"}.Table 3Advantages and disadvantages of the new oral anticoagulants relative to warfarinClassAdvantagesDisadvantagesOral direct IIa/Xa blockersMore effective against thromboembolism than VKANo monitoring in case of bleeding or urgent surgeryFast onset of actionNot applicable in severe renal failure (CrCl \< 30 ml/min)Fast offset of action (in case of bleeding/surgery)Not applicable in carriers of artificial heart valvesBetter safety, especially less intracranial bleeding than VKAShort duration of action (thrombosis risk with poor complianceEase (no monitoring)Antidote strategy not establishedSome agents have interaction with anti-arrhythmic agentsVitamin K antagonistsTherapeutic window establishedMonitoring of INRAntidote algorithm establishedDrug interaction with many agentsLong duration of actionFood interaction(low thrombosis risk with poor compliance)Slow onset of actionHigh bleeding risk, intracranial bleeding in particular*VKA* vitamin K antagonists, *IIa* activated factor II (thrombin), *Xa* activated factor X

The trials and registries {#Sec3}
=========================

In atrial fibrillation the direct oral thrombin (factor IIa) inhibitor ximelagatran is as effective as warfarin and reduces major bleeding \[[@CR10], [@CR11]\], but the drug is associated with liver toxicity, which withholds its approval and further marketing. Another direct oral thrombin blocker, dabigatran, has been evaluated in comparison with warfarin in the huge phase III RE-LY trial in atrial fibrillation \[[@CR12]\]. Finally, oral direct factor Xa blockers have become available and are effective in the prevention and treatment of deep vein thrombosis and pulmonary embolism \[[@CR13]--[@CR18]\]. Rivaroxaban, apixaban and edoxaban have been tested for stroke prevention in atrial fibrillation (Table [4](#Tab4){ref-type="table"}) \[[@CR19], [@CR20]\]. Except for edoxaban, where results will be available shortly, they show better or equal efficacy compared with warfarin at no excess bleeding \[[@CR12], [@CR19], [@CR20]\]. As shown in Table [4](#Tab4){ref-type="table"}, the trials differ in design in that RE-LY is open label and the other double blind, by which INR is measured at the point of care and sham INRs are computer-generated for the patients randomised to the new agent. Double-blind controlled trials are the highest standard of quality in evidence-based medicine and also in the case of INR monitored trials blinding is feasible and successful \[[@CR11]\]. Open-label studies have the serious shortcoming of treatment bias. In case of bleeding with open-label warfarin, physicians will react differently than with bleeding with a drug that could be either an experimental short-acting new oral anticoagulant or warfarin. Therefore, the design of RE-LY makes its outcome on softer endpoints doubtful. A good example of this is the differential results of the studies where ximelagatran was compared with warfarin in stroke prevention for atrial fibrillation. SPORTIF-III was an open-label trial and stroke prevention tended to be better with ximelagatran than with warfarin \[[@CR10]\], but in SPORTIF-V with its double-blind design it was the other way around \[[@CR11]\]. The ximelagatran arms of both trials had an almost identical outcome making both studies highly comparable in baseline features. Although complex to perform, trials of the new oral anticoagulants had to be double-blind in design. The trials in evidence-based medicine we use nowadays were tested double-blind in the 1990s, such as those on beta blockers, aspirin, statins and ACE inhibitors.Table 4Phase III trials with new oral anticoagulants in atrial fibrillationClassNameComparatorDesign*n*TrialAnti-IIa (antithrombin)DabigatranWarfarin (clinic)Open18,133RE-LY \[[@CR12]\]Anti-XaApixabanWarfarin (point of care)Double-blind14,264ROCKET-AF \[[@CR19]\]RivaroxabanWarfarin (point of care)Double-blind18,201ARISTOTLEF \[[@CR20]\]EdoxabanWarfarin (point of care)Double-blind\> 21,000ENGAGE AF TIMI-48^a^*IIa* activated factor II (thrombin), *Xa* activated factor X, *n* number of patients^a^to be presented late 2013

By design, the trials included both warfarin-experienced and warfarin-naive patients and by stratification the results on both efficacy and bleeding proved similar in the three trials. This suggests that newcomers with atrial fibrillation benefit from the new drugs as well as those who have been switched from warfarin to the new strategy. However, these are post-hoc analyses, which have been heavily criticised in this kind of trial in atrial fibrillation, such as the ACTIVE-W study \[[@CR21]\].

Finally, until recently there were no data on the long-term safety and efficacy of the new drugs. But, recently, a more than 4-year follow-up study of about half of the patients on both doses of dabigatran in the RE-LY trial, who continued the drug, was published \[[@CR22]\]. It showed acceptable gastrointestinal bleeding and stroke data, but this was a highly selected population without a control group, which does not definitively confirm dabigatran's safety \[[@CR23]\]. On the other hand, a mini-sentinel analysis by the Food and Drug Administration in the US also showed a favourable safety profile of dabigatran when compared with warfarin \[[@CR24]\]. In five trials of controlled studies with dabigatran in the prevention and treatment of thrombosis, fatal bleeding was lower than with warfarin \[[@CR25]\], which confirmed another meta-analysis of all new agents versus warfarin \[[@CR26]\]. Although there is still no effective specific antidote for the new drugs, these data make the development of such an antidote less urgent. Unspecific regimens such as prothrombin concentrate complex (Cofact^R^) seem to be a reasonable alternative for the inactivation of the Xa blocker rivaroxaban, but not the IIa blocker dabigatran, but this has only been tested in young healthy volunteers \[[@CR27]\].

Introduction of the new oral anticoagulants {#Sec4}
===========================================

It took quite a while in the Netherlands before the new agents became eligible for reimbursement after approval for their use in atrial fibrillation \[[@CR28]\], when compared with other regions in the EU and in the rest of the world. The reimbursement will not affect the cardiology budgets. The government produced a report about appropriate use \[[@CR29]\] and the national society of medical specialists published a broadly based guideline for safe utilisation \[[@CR30]\] of the new oral anticoagulants for the various indications. Not general practitioners, but only medical specialists such as cardiologists, orthopaedic surgeons, neurologists and internists are allowed to prescribe the agents. Finally, major and life-threatening bleeding must be reported according to the Lareb Intensive Monitoring Program ([www.lareb.nl](http://www.lareb.nl/)). The checklist derived from the national guideline is summarised in Table [5](#Tab5){ref-type="table"}.Table 5Checklist for safe use of the new oral anticoagulants \[[@CR26]\]OrganisationA local protocol for handling of bleeding and/or surgery must be writtenPrescriptionFill out the doctor's statement and explain transition if the patient is on VKARenal functionCreatinine clearance should be more than 30 ml/minTransitionStop VKA and wait for the INR to be \< 2.0 before starting NOACElective major procedureStop NOAC 24--48 h ahead according to renal function, no bridgingElective minor procedureConsider NOAC continuationMinor bleedingConsider NOAC continuationModerate bleedingSkip one NOAC dose and perform haemostasisMajor bleedingStop NOAC, perform haemostasis and consider Cofact^R^ and/or Cyclokapron^R^Life-threatening bleedingAll of the above and consider Novoseven^R^Reporting of bleedingSevere bleeding must be reported to Lareb Monitoring Program ([www.lareb.nl](http://www.lareb.nl/))*VKA* vitamin K antagonist, *INR* International Normalised Ratio, *NOAC* new oral anticoagulant

Recently, the European Heart Rhythm Association published a very useful and more extensive practical guide on the use of the new agents in atrial fibrillation \[[@CR31]\]. In this paper also drug interactions are described more in detail as well as what to do with cardioversion and with patients suffering from comorbidities: coronary artery disease treated with or without revascularisation, acute stroke and cancer.

Conclusion {#Sec5}
==========

From the current trials it has become clear that oral direct inhibition of the major haemostatic proteins factor IIa or factor Xa is at least as effective as warfarin in stroke prevention of atrial fibrillation with a safety profile which is far more favourable than warfarin, especially where intracranial bleeding is concerned. The lack of monitoring will be the major reason for many physicians to switch from warfarin to the new agents and to put newcomers with atrial fibrillation without anticoagulants on them right away.

The current absence of an antidote has not led to catastrophic bleeding in the trials and the recent registries. The only significant clinical drawback is that the new agents cannot be used in patients with severe renal failure and in those with artificial heart valves.
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